|
|
|
European Biopharmaceutical Review
|
| The world’s first measles, rubella, hepatitis
B, meningitis and cervical cancer vaccines
were developed in Wallonia. The Frenchspeaking
region in southern Belgium also
hosts world leaders in epilepsy treatment
and proton therapy for cancer. Drug
manufacturers in Wallonia, working in
tandem with university laboratories on
R&D, have also contributed to major
advances in the fight against global
pandemics such as tuberculosis, malaria,
AIDS, cancer and neurodegenerative
diseases.
For nearly 50 years, Wallonia
has been fostering understanding and
know-how in molecular biology, genomics,
proteomics, stem cells, medical appliances
and equipment – all cutting-edge
technologies in the life sciences field, up to
and including cell research (such as ADN,
ARN, proteins and human genomes) and
the development of innovative diagnostics
and therapies.
BIOTECHNOLOGY IN WALLONIA
With 76 biotechnology companies,
representing 74 per cent of Belgian
biotechnology, the industry in this region
has an annual turnover of €2.7 billion,
with 80 per cent of its work focused on
healthcare, and employs about 10,000
people.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Dr Philippe Janssens de Varebeke is a Life Sciences expert at
Wallonia Export & Investment (AWEX) in Brussels, Belgium. He
holds a PhD in Biochemistry and started his career at the University
of Louvain. He then worked within several departments of G.D.
SEARLE, part of the Monsanto group in Belgium, for over 12 years.
After this, he became investment manager in venture capital funds
with Euro Ventures Benelux before joining the University of Louvain. Here he was
involved in the creation of spin-off companies, becoming senior investment manager
of SOPARTEC and the VIVES fund. He is board member of several life sciences
companies. Over the last two years, he has been part of AWEX as Life Sciences Expert
for foreign investment projects. He is author of many publications, patents and books
including the reference book Biotech Opportunities in Europe: Establishing and
Operating a health Care Biotech Venture.
Frédéric Druck is BioWin’s Communication Director. He has a degree
in journalism and communication from the Université Libre de
Bruxelles, where he also began his career as an assistant lecturer. He
then developed his professional expertise in corporate communication
and public relations in positions of responsibility at employers’
organisations (UPEDI, Federgon). He acquired his knowledge of the
health sector while working at Merck Sharp & Dohme Belgium, a European subsidiary
of Merck & Co. He also worked at Interel, a Belgian public relations consultancy that
works with various pharmaceutical companies, where he was in charge of the medical
department. At BioWin, Frédéric has responsibility for the cluster’s communication,
networking activities and international relations. |
|
|
|
|
|
 |
Industry Events |
 |
BIO-Europe Spring® 2012 — 6th International Partnering Conference
19-21 March 2012, Amsterdam RAI Convention Center, Amsterdam, The Netherlands
BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
